Retrospective comparison of survival and responses to Fludarabine, Cytarabine, GCSF (FLAG) in combination with gemtuzumab ozogamicin (GO) or Idarubicin (IDA) in patients with newly diagnosed core binding factor (CBF) acute myelogenous leukemia
Kazemi, A., Shojaei-Zarghani, S., Eskandarzadeh, P., & Hashempur, M
Echocardiogram and electrocardiogram, as well as a chromosomal microarray and fragile X syndrome molecular testing, were normal
The major neuropathology after H/I insult begins during the acute insult and extends into the reperfusion phase (49)
however, in some vacuoles in contact with the void zone of the cho1 cells, these proteins were excluded from the contact area (Figure 6C)